Author

E. C. Thomson

Listed by name: these papers carry no ORCID for this author, so different people with the same name may be mixed together.

Biology Disciplines

Click to filter author papers

Microbiology· 7 Immunology· 1

Signature Assays, Organisms & Methods

Click to filter · or open tag

Research Focus:host-pathogen & immune response· 6 Approach:experimental assay· 5 Organism:human· 5 Assay:proteomics· 3 Approach:statistical model· 3 Assay:bulk RNA-seq· 2 Research Focus:differential expression· 2 Research Focus:drug response / drug discovery· 2

Frequent Co-Authors

B. J. Willett· 3 shared C. Davis· 3 shared L. Tong· 3 shared A. D. S. Filipe· 2 shared A. da Silva Filipe· 2 shared A. Kohl· 2 shared A. M. Szemiel· 2 shared A. Wickenhagen· 2 shared

Activity by Year

2020-2024 · peak 2/yr

Co-Author Collaboration Network

10 top collaborators · 27 mutual co-author links

Click any collaborator node to inspect or filter shared papers

Focal author (center)Selected co-authorORCID co-authorUnlinked name

Curved chords = mutual co-authorship

3 shared papersMicrobiology

B. J. Willett

Mutual co-authors in cluster

Author profile →

8 papers

Recent·Most cited

Global variation in prior exposure shapes antibody neutralization profiles of SARS-CoV-2 variants up to BA.2.86

S. Turner, G. Amirthalingam, D. Bailey, D. H. Barouch, K. R. Bewley, K. Brown, Y. R. Cao, Y.-W. Chan, S. Charlton, DOVE consortium, N. S. Coombes, B. Hallis, D. D. Ho, F. Jian, N. Lasrado, , D. J. Smith

The paper analyzes antibody neutralization data from multiple countries to assess how prior exposure to SARS-CoV-2 variants affects neutralization profiles of BA.2.86 and its descendants.

bioRxiv · Mar 27, 2024 · PreprintImmunology

Epidemiological inference at the threshold of data availability: an influenza A(H1N2)v spillover event in the United Kingdom

J. A. Fozard, E. C. Thomson, C. Illingworth

The paper estimates the timeline and parameters of an influenza A(H1N2)v spillover event using likelihood-free rejection sampling with limited data.

bioRxiv · Mar 11, 2024 · PreprintMicrobiology

Temperature elevation synergises with and enhances the type-I IFN-mediated restriction of MPXV

C. Davis, I. Epifano, K. Dee, S. McFarlane, J. K. Wojtus, B. Brennan, Q. Gu, S. B. Vattipally, L. Tong, L. Orr, A. D. S. Filipe, D. A. Barr, A. Ho, E. C. Thomson, C. Boutell

This study shows that fever enhances the host's type-I IFN response to restrict MPXV replication.

bioRxiv · Sep 29, 2023 · PreprintMicrobiology

Ticks; a reservoir for virus emergence at the human-livestock interface in Uganda

S. A. Atim, S. Ashraf, M. Niebel, A. Ssekagiri, M. N. Hardy, J. G. Shepherd, L. Tong, A. R. Ademun, P. Vudriko, J. Erume, S. Odongo, D. Muhanguzi, W. Nguma, T. Nakayiki, J. Namulondo, , E. C. Thomson

The paper sequences ticks in Uganda to identify viruses, finding 22 species including 8 pathogens and 5 novel viruses, with orthonairoviruses being prevalent.

bioRxiv · Mar 10, 2023 · PreprintMicrobiology

Distinct antigenic properties of the SARS-CoV-2 Omicron lineages BA.4 and BA.5

B. J. Willett, A. Kurshan, N. Thakur, J. Newman, M. Manali, G. Tyson, N. Logan, P. R. Murcia, L. B. Snell, J. D. Edgeworth, J. Zhou, K. Sukhova, G. Amirthalingam, K. Brown, B. Charleston, , T. P. Peacock

This study compares the antigenic properties of SARS-CoV-2 Omicron variants BA.4 and BA.5 with BA.1, BA.2, and vaccine-induced antibodies, finding they are antigenically distinct and show enhanced neutralisation breadth after breakthrough infection.

bioRxiv · May 25, 2022 · PreprintMicrobiology

COVID-19: A need for new rather than repurposed antiviral drugs.

D. Kovacs, C. Davis, P. Cannon, M. McFarlane, S. M. Rainey, R. Pinto, M. E. Stewart, A. M. Szemiel, A. Taggart, A. Kohl, F. Marra, E. C. Thomson, J. T. Scott

This paper reviews 29 FDA-approved antiviral compounds for COVID-19 treatment, finds limited clinical efficacy of repurposed drugs, and highlights the need for novel antivirals.

bioRxiv · Mar 25, 2021 · PreprintMicrobiology

In vitro evolution of Remdesivir resistance reveals genome plasticity of SARS-CoV-2

A. M. Szemiel, A. Merits, R. J. Orton, O. MacLean, A. Wickenhagen, G. Lieber, R. M. Pinto, M. L. Turnbull, S. Wang, D. Mair, A. da Silva Filipe, B. J. Willett, S. J. Wilson, A. H. Patel, E. C. Thomson, , M. E. Stewart

This study shows that in vitro evolution of SARS-CoV-2 under remdesivir selects for resistant mutations, but these mutations do not spread widely in global variants.

bioRxiv · Feb 1, 2021Microbiology

The circulating SARS-CoV-2 spike variant N439K maintains fitness while evading antibody-mediated immunity

E. C. Thomson, L. E. Rosen, J. G. Shepherd, R. Spreafico, A. da Silva Filipe, J. A. Wojcechowskyj, C. Davis, L. Piccoli, D. J. Pascall, J. Dillen, S. Lytras, N. Czudnochowski, R. Shah, M. Meury, N. Jesudason, , J. Nichols

The paper shows the N439K SARS-CoV-2 spike variant maintains replication fitness while evading antibody neutralization.

bioRxiv · Nov 4, 2020Microbiology